Platelet aggregation in response to ADP is highly variable in normal donors and patients on anti-platelet medication.
Eimear DunneKarl EganSiobhán McFaddenDavid FoleyDermot KennyPublished in: Clinical chemistry and laboratory medicine (2017)
The results of our study demonstrate that 15% of normal donors and 38% of patients taking aspirin only would be classified as having a therapeutic response to P2Y12 inhibition using current guidelines.